Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
- Revenue in EUR (TTM)94.34m
- Net income in EUR47.80m
- Incorporated1999
- Employees134.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Mergers & acquisitions
| Acquired company | GNFT:PAR since announced | Transaction value |
|---|---|---|
| Versantis AG | -14.46% | 108.85m |
Data delayed at least 15 minutes, as of Dec 02 2022 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pcas SA | 190.57m | -67.46m | 108.41m | 1.18k | -- | -- | -- | 0.5689 | -4.91 | -4.91 | 13.87 | -0.0734 | 0.6298 | 1.76 | 5.76 | 162,738.70 | -22.29 | -4.98 | -63.25 | -8.49 | 29.90 | 41.29 | -35.40 | -6.53 | 0.3374 | -15.39 | 1.01 | -- | -3.66 | -0.5247 | -170.81 | -- | 12.84 | -- |
| Eurofins-Cerep SA | 41.62m | 9.84m | 111.98m | 197.00 | 11.38 | 2.47 | 10.03 | 2.69 | 1,951.38 | 1,951.38 | 8,257.30 | 9,003.02 | 0.7868 | 2.41 | 6.40 | 211,252.70 | 18.61 | 14.15 | 23.21 | 17.77 | 86.29 | 59.01 | 23.65 | 17.72 | 3.70 | 13.88 | 0.0623 | -- | 27.40 | 12.17 | 76.48 | 31.68 | -- | -- |
| Aelis Farma SA | 3.14m | -13.56m | 122.14m | 24.00 | -- | 5.11 | -- | 38.85 | -1.19 | -1.19 | 0.2669 | 1.91 | 0.0824 | -- | 1.34 | 131,000.00 | -35.51 | -- | -55.15 | -- | -- | -- | -431.23 | -- | 2.85 | -0.9617 | 0.0794 | -- | -- | -- | 127.52 | -- | -- | -- |
| Ose Immunotherapeutics SA | 33.38m | -7.34m | 132.29m | 60.00 | -- | 2.82 | -- | 3.96 | -0.3998 | -0.3998 | 1.81 | 2.53 | 0.333 | -- | 58.56 | 547,180.30 | -7.32 | -9.88 | -9.23 | -11.76 | -- | -- | -21.99 | -45.90 | -- | -6.62 | 0.4332 | -- | 152.17 | 133.01 | -1.78 | -- | 73.53 | -- |
| Nanobiotix SA | 0.00 | -42.94m | 135.12m | 103.00 | -- | 75.46 | -- | -- | -1.23 | -1.23 | 0.00 | 0.0514 | 0.00 | -- | -- | 0.00 | -41.99 | -52.22 | -69.30 | -66.48 | -- | -- | -- | -37,902.42 | -- | -- | 0.9593 | -- | -80.00 | -63.57 | -39.93 | -- | -- | -- |
| Biosynex SA | 299.54m | 64.10m | 148.66m | 328.00 | 2.53 | 0.8413 | 2.03 | 0.4963 | 5.73 | 5.73 | 26.68 | 17.24 | 1.18 | 2.63 | 21.28 | 1,105,327.00 | 27.34 | 34.59 | 37.50 | 46.94 | 47.95 | 51.67 | 23.15 | 22.28 | 3.41 | 760.56 | 0.1715 | 16.36 | 148.57 | 69.88 | 231.54 | -- | -- | -- |
| AFYREN SA | 3.28m | -6.23m | 151.48m | 70.00 | -- | 2.03 | -- | 46.23 | -0.3152 | -0.3152 | 0.1671 | 2.90 | 0.0532 | -- | 7.67 | 46,814.29 | -10.11 | -- | -11.41 | -- | 94.35 | -- | -190.05 | -- | -- | -1.67 | 0.1033 | -- | -23.93 | -- | -69.20 | -- | -- | -- |
| Abivax SA | 0.00 | -54.38m | 155.30m | 24.00 | -- | -- | -- | -- | -3.08 | -3.08 | 0.00 | -0.0448 | 0.00 | -- | -- | 0.00 | -85.81 | -43.17 | -167.65 | -61.15 | -- | -- | -- | -- | -- | -27.48 | 1.02 | -- | -- | -- | -10.14 | -- | -42.08 | -- |
| Medincell SA | 4.09m | -24.81m | 158.46m | 156.00 | -- | -- | -- | 38.74 | -0.9975 | -0.9975 | 0.1645 | -0.5325 | 0.0758 | 7.50 | 6.39 | 26,217.95 | -45.98 | -51.57 | -88.49 | -74.58 | 63.23 | 75.62 | -606.50 | -421.41 | 0.8844 | -25.20 | 1.44 | -- | -50.04 | -- | -30.65 | -- | -- | -- |
| Gensight Biologics SA | 2.76m | -31.03m | 164.49m | 44.00 | -- | 51.36 | -- | 59.51 | -0.6755 | -0.6755 | 0.0604 | 0.0691 | 0.0512 | -- | 2.22 | 72,736.84 | -57.52 | -63.75 | -87.71 | -83.23 | -- | -- | -1,122.58 | -1,456.76 | -- | -- | 0.834 | -- | 20.07 | -- | 15.87 | -- | -29.91 | -- |
| Genfit SA | 94.34m | 47.80m | 172.23m | 134.00 | 5.30 | 1.58 | 3.43 | 1.83 | 0.6524 | 0.6524 | 1.61 | 2.19 | 0.5089 | 485.25 | 145.25 | 842,312.50 | 25.79 | -18.67 | 31.40 | -21.82 | 97.94 | 93.39 | 50.67 | -157.66 | 6.33 | -- | 0.3957 | -- | 1,003.11 | 66.03 | 166.45 | -- | -23.40 | -- |
| Inventiva SA | 4.12m | -55.97m | 175.28m | 109.00 | -- | 2.51 | -- | 42.52 | -1.39 | -1.39 | 0.1024 | 1.65 | 0.0365 | -- | 1,030.50 | 41,220.00 | -49.61 | -38.16 | -59.96 | -45.17 | -- | -- | -1,357.74 | -849.65 | 4.14 | -- | 0.21 | -- | 1,027.42 | -14.99 | -47.64 | -- | 18.56 | -- |
| Innate Pharma SA | 45.08m | -15.38m | 178.87m | 213.00 | -- | 1.53 | -- | 3.97 | -0.1914 | -0.2837 | 0.5637 | 1.46 | 0.1649 | -- | 8.99 | 209,669.80 | -5.63 | -6.65 | -7.15 | -9.58 | 93.71 | 92.81 | -34.12 | -45.00 | -- | -- | 0.5004 | -- | -78.43 | -26.42 | -5,385.89 | -- | -32.35 | -- |
| Transgene SA | 18.12m | -23.02m | 188.78m | 165.00 | -- | 3.47 | -- | 10.42 | -0.2337 | -0.2337 | 0.1842 | 0.5429 | 0.1881 | -- | 6.55 | 108,473.10 | -23.89 | -15.27 | -27.55 | -18.27 | -- | -- | -127.05 | -147.28 | -- | -- | 0.0556 | -- | 82.10 | 14.28 | -13.38 | -- | 90.14 | -- |
| Guerbet SA | 740.03m | 12.59m | 217.43m | 2.73k | 17.36 | 0.5060 | 3.07 | 0.2938 | 0.9908 | 0.9908 | 58.09 | 33.99 | 0.753 | 0.8612 | 5.65 | 271,072.90 | 1.28 | 3.62 | 1.67 | 5.04 | 73.79 | 75.55 | 1.70 | 4.70 | 1.03 | 9.86 | 0.4208 | 27.45 | 2.78 | -1.15 | 78.93 | 2.44 | -0.3443 | 0.00 |
| Eurobio Scientific SA | 172.74m | 46.71m | 223.69m | 165.00 | 4.39 | 1.33 | 3.98 | 1.29 | 4.50 | 4.50 | 16.64 | 14.88 | 0.8777 | 5.03 | 4.47 | 1,046,885.00 | 23.73 | 24.13 | 28.50 | 34.46 | 51.05 | 50.52 | 27.04 | 23.66 | 4.58 | -- | 0.0763 | 0.00 | -2.19 | 46.13 | -17.61 | -- | 55.99 | -- |
Data as of Dec 02 2022. Currency figures normalised to Genfit SA's reporting currency: Euro EUR
2.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Healthinvest Partners ABas of 30 Jun 2022 | 325.00k | 0.65% |
| Goldman Sachs Asset Management Internationalas of 30 Sep 2022 | 306.68k | 0.62% |
| American Century Investment Management, Inc.as of 03 Nov 2022 | 75.67k | 0.15% |
| Sunny Asset Management SAas of 27 Oct 2022 | 70.00k | 0.14% |
| Mandarine Gestion SAas of 29 Jul 2022 | 63.00k | 0.13% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 55.62k | 0.11% |
| PKB PRIVATBANK SAas of 25 Sep 2020 | 50.00k | 0.10% |
| Dimensional Fund Advisors LPas of 03 Nov 2022 | 48.19k | 0.10% |
| Abeille Asset Management SAas of 31 Dec 2019 | 31.13k | 0.06% |
| Bessemer Investment Management LLCas of 29 Jul 2022 | 16.18k | 0.03% |
More ▼
Data from 31 Dec 2021 - 24 Nov 2022Source: FactSet Research Systems Inc.
